Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Fibroblastic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Mesenchymal Cell Neoplasm
Fibroblastic Neoplasm

Cancer Family

Fibroblastic Neoplasm

CI-CAN-00000181Explore in graph →

Non-malignant45 active trials52 evidence items

NCIt: C7075

Overview
Statistics
Survival
Genomics
Variants & evidence52
Drugs6
Trials203
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (35)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 35 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
· Lancet Oncol · 2018 · PMID 29606586 · validated civic_curation pubmed
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
· Nat Genet · 1998 · PMID 9462753 · validated civic_curation pubmed
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
· J Clin Oncol · 2017 · PMID 28787259 · validated civic_curation pubmed
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
· Am J Hematol · 2018 · PMID 29352732 · validated civic_curation pubmed
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
· Lancet Oncol · 2013 · PMID 23598171 · validated civic_curation pubmed
Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
· Am J Pathol · 2008 · PMID 18832571 · validated civic_curation pubmed
CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics.
· Mod Pathol · 2012 · PMID 22766794 · validated

Showing 1–25 of 35 publications

← Previous
1
2
Next →

civic_curation

β-Catenin mutation status and outcomes in sporadic desmoid tumors.

· Oncologist · 2013 · PMID 23960186 · validated civic_curation pubmed

Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays.

· Hum Pathol · 2008 · PMID 17950782 · validated civic_curation pubmed

Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.

· Ann Surg Oncol · 2015 · PMID 25341748 · validated civic_curation pubmed

Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group.

· Am J Surg Pathol · 2007 · PMID 17721195 · validated civic_curation pubmed

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed

Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays.

· Hum Pathol · 2011 · PMID 21111450 · validated civic_curation pubmed

Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans.

· Mod Pathol · 2007 · PMID 17431412 · validated civic_curation pubmed

Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.

· Am J Surg Pathol · 2000 · PMID 10895816 · validated civic_curation pubmed

Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues.

· Am J Clin Pathol · 2001 · PMID 11242790 · validated civic_curation pubmed

Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing.

· Br J Dermatol · 2022 · PMID 35441365 · validated civic_curation pubmed

In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets.

· Clin Cancer Res · 2017 · PMID 28939748 · validated civic_curation pubmed

Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens.

· Am J Surg Pathol · 2006 · PMID 16931951 · validated civic_curation pubmed

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

· N Engl J Med · 2010 · PMID 20979472 · validated civic_curation pubmed

Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.

· Cancer Res · 1999 · PMID 10383129 · validated civic_curation pubmed

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

· Cancer Res · 2010 · PMID 21030459 · validated civic_curation pubmed

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

· Cancer Discov · 2014 · PMID 24875859 · validated civic_curation pubmed

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.

· Cancer · 2018 · PMID 30204247 · validated civic_curation pubmed

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure.

· Onco Targets Ther · 2018 · PMID 29760553 · validated civic_curation pubmed